Article Text
P2. Immunoablation and t cell depleted autologous peripheral blood stem cell rescue as effective treatment for long term progressive rheumatoid arthritis refractory to multiple conventional treatment
P3. Cd34 positive selection of cryopreserved peripheral blood stem cells (PBSC) for autologous transplantation in a patient with wegener's granulomatosis
P4. Infiltrate analysis of rheumatoid synovial tissue before and after high dose chemotherapy and autologous stem cell transplantation
P5. Autologous stem cell transplantation (ASCT) after high dose immunosuppressive (HDI) treatment in rheumatoid arthritis (RA): clinical and pathological correlations
P6. Long term follow up of highly selected autologous stem cell transplantation (ASCT) in severe rheumatoid arthritis with studies of peripheral blood and synovial lymphocyte reconstitution
P7. Quality of life of patients with multiple sclerosis after autologous peripheral stem cell transplantation
P8. High dose melphalan with stem cell support for the refractory immune thrombocytopenic purpura (ITP): a case report
P9. Autologous haemopoietic stem cell transplantation (HSCT) for paraneoplastic cerebellar degeneration: a case report
P10. Autologous stem cell transplantation for multiple sclerosis in russia
Abstract
Patients and methods: In 1999–2000 in the Bone Marrow Transplantation Unit of the Military Medical Academy (St Petersburg) three autologous stem cell transplantations (ASCT) were carried out for patients with multiple sclerosis (MS). All the patients were women, aged 21–48 years, with considerable disability. The Kurtzke Expanded Disability Status Scale (EDSS) was used for clinical neurological assessments. Two patients had secondary progredient subtype (EDSS 5 and 7.5 respectively) and the third patient had a primary remitting subtype of MS (EDSS 4). According to the protocol stem cells were mobilised by G-CSF 10 mg/kg subcutaneously; leukaphereses on days 4, 5, 6; conditioning regimen BEAM and ATGAM (Upjohn) 60 mg/kg. Stem cells were reinfused on day 0. For shortening myelosuppression G-CSF were used at 5 mg/kg subcutaneously; a 500 neutrophil/ml level was achieved on day 11 or 12. Platelet level was 50 × 109/l on days 22–28.
Results: On day 30 after ASCT two patients improved by 0.5 and 1 EDSS points respectively. One improvement was striking and of great importance to the patient. The third patient had no changes according to the EDSS and remained stable.
All patients had achieved complete remission between 3 and 15 months.